8. ADN Tumoral Circulante: nuevo factor  pronóstico en el cáncer de colon  estadio II

Flora López López

Flora López López Oncología Médica. Hospital Universitario del Sureste (Arganda del Rey), Madrid

Palabras clave: Cáncer de colon, Adyuvancia, Biopsia líquida

Abstract

La quimioterapia adyuvante (QA) en el cáncer de colon estadio II resecado sigue siendo controvertida. Actualmente se emplea en aquellos pacientes con factores clínicos o patológicos de riesgo añadidos. La detección de DNA tumoral circulante (ctDNA) en biopsia líquida se ha estudiado como potencial factor pronóstico en este escenario. Es interesante su implementación para ayudar en la toma de decisiones terapéuticas.

Adjuvant chemotherapy (AQ) in resected stage II colon cancer remains controversial and is currently used in patients with added clinical or pathological risk factors. Positive circulating tumour DNA (ctDNA) in liquid biopsy has been studied as a potential prognostic factor in this scenario, so can be useful tool in therapeutic decision-making.

Recibido: 06 Abril 2023
Revisión: 11 Abril 2023
Aceptado: 05 Mayo 2023

Citas

Vol. 2008 N3; CD005390. 2008. Figueredo A, Coombes M.E and Mukherjee S. Adjuvant Therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. doi: https://doi.org/10.1002/14651858.cd005390.pub2

Vol. 12 N9; págs. 2584. 2020. Rebuzzi SE, Pesola G, Martelli V, Sobrero AF. Adjuvant Chemotherapy for Stage II Colon Cancer. Cancers (Basel). doi: https://doi.org/10.3390%2Fcancers12092584

Vol. 31 N10; págs. 1291-1305. 2020. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. doi: https://doi.org/10.1016/j.annonc.2020.06.022

Vol. 5; N8; págs. 1124-1131. 2019. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology. doi: https://doi.org/10.1001/jamaoncol.2019.0528

Vol. 17; N12; págs. 757-770. 2020. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nature Reviews Clinical Oncology. doi: https://doi.org/10.1038/s41571-020-0392-0

Vol. 8; N346; págs. 346ra92. 2016. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine. doi: https://doi.org/10.1126/scitranslmed.aaf6219

Vol. 39; N6; págs. 631-641. 2021. Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, et al. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. Journal of Clinical Oncology. doi: https://doi.org/10.1200/jco.20.01330